Improving overall survival and overcoming adverse prognosis in the treatment of cytogenetically high-risk multiple myeloma

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study

(2012) L. Rosinol et al.   BLOOD

Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma

(2012) M. Cavo et al.   BLOOD

Clonal competition with alternating dominance in multiple myeloma

(2012) J. J. Keats et al.   BLOOD

Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

(2012) Pieter Sonneveld et al.   JOURNAL OF CLINICAL ONCOLOGY

Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial

(2012) P. Joy Ho et al.   LEUKEMIA & LYMPHOMA

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcome according to cytogenetic abnormalities and DNA ploidy in myeloma patients receiving short induction with weekly bortezomib followed by maintenance

(2011) M.-V. Mateos et al.   BLOOD

Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation

(2011) G. J. Morgan et al.   BLOOD

Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

(2011) K. Neben et al.   BLOOD

Approach to the treatment of multiple myeloma: a clash of philosophies

(2011) S. V. Rajkumar et al.   BLOOD

The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis

(2011) G. J. Morgan et al.   BLOOD

Impact of high-risk classification by FISH: an Eastern Cooperative Oncology Group (ECOG) study E4A03

(2011) Susanna J. Jacobus et al.   BRITISH JOURNAL OF HAEMATOLOGY

The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide-based therapy

(2011) Kevin D. Boyd et al.   GENES CHROMOSOMES & CANCER

Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results

(2011) G. J. Morgan et al.   HAEMATOLOGICA

A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial

(2011) K D Boyd et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Mechanism of Action of Proteasome Inhibitors and Deacetylase Inhibitors and the Biological Basis of Synergy in Multiple Myeloma

(2011) T. Hideshima et al.   MOLECULAR CANCER THERAPEUTICS

Translocation t(14;16) and multiple myeloma: is it really an independent prognostic factor?

(2010) H. Avet-Loiseau et al.   BLOOD

Superior results of Total Therapy 3 (2003-33) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006-66 with VRD maintenance

(2010) B. Nair et al.   BLOOD

Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma

(2010) H. Ludwig et al.   HAEMATOLOGICA

Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma

(2010) D. Hose et al.   HAEMATOLOGICA

Bortezomib Plus Dexamethasone Induction Improves Outcome of Patients With t(4;14) Myeloma but Not Outcome of Patients With del(17p)

(2010) Hervé Avet-Loiseau et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study

(2010) Michele Cavo et al.   LANCET

Bortezomib, melphalan, and prednisone versus bortezomib, thalidomide, and prednisone as induction therapy followed by maintenance treatment with bortezomib and thalidomide versus bortezomib and prednisone in elderly patients with untreated multiple myeloma: a randomised trial

(2010) María-Victoria Mateos et al.   LANCET ONCOLOGY

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Influence of cytogenetics in patients with relapsed or refractory multiple myeloma treated with lenalidomide plus dexamethasone: adverse effect of deletion 17p13

(2009) D. Reece et al.   BLOOD

Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone

(2009) P. Kapoor et al.   BLOOD

P53deletion may drive the clinical evolution and treatment response in multiple myeloma

(2009) Lucía López-Anglada et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

International Myeloma Working Group molecular classification of multiple myeloma: spotlight review

(2009) R Fonseca et al.   LEUKEMIA

Thalidomide arm of Total Therapy 2 improves complete remission duration and survival in myeloma patients with metaphase cytogenetic abnormalities

(2008) B. Barlogie et al.   BLOOD

Sustained complete remissions in multiple myeloma linked to bortezomib in total therapy 3: comparison with total therapy 2

(2008) Mauricio Pineda-Roman et al.   BRITISH JOURNAL OF HAEMATOLOGY

Prediction of Survival in Multiple Myeloma Based on Gene Expression Profiles Reveals Cell Cycle and Chromosomal Instability Signatures in High-Risk Patients and Hyperdiploid Signatures in Low-Risk Patients: A Study of the Intergroupe Francophone du Myélome

(2008) Olivier Decaux et al.   JOURNAL OF CLINICAL ONCOLOGY

Genetic aberrations and survival in plasma cell leukemia

(2008) R E Tiedemann et al.   LEUKEMIA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE